Q3 2020 Sales Performance

Vir collaboration: potential best-in-class antibody for COVID-19 Differentiated antibody approach ■ Vir-7831 potently neutralises SARS-CoV-2 High barrier of resistance1 due to unique binding properties and a highly conserved epitope Highly potent allowing for a lower dose and has the ability to recruit other immune cells to kill already infected cells 2,3 Has a "LS mutation"5 DYING PNEUMOCYTES VIR-7831 UNFECTED PHEROCYTES Neutralizes virus 1. 2. Kills infected cells 3. Has a high barrier to resistance which extends the antibody half life and increases the amount of the drug in the lung COMET-ICE study ongoing in patients at high risk of hospitalisation; preliminary data expected by end 2020 Significant unmet need ■ Clear need for therapeutics despite active vaccine development programmes Significant demand for COVID-19 mAbs gsk ■ Around 5% of infections are thought to require hospitalisation, based on data to date Additional opportunities planned ■ Phase 3 study in hospitalised patients with severe COVID-19 ■ Phase 3 study for prevention of symptomatic infection ■ Vir-7832 Phase 2 study 1. Adapted from Pinto et al. Nature (published online May 18, 2020). https://doi.org/10.1038/s41586-020-2349-y 2. Piccoli et al, Cell (published online September 16, 2020). https://doi.org/10.1016/j.cell.2020.09.037 3. Schafer et al, BioRxib (published on line September 15, 2020). https://doi.org/10.1101/2020.09.15.298067 4. Vir Investor Presentation https://investors.vir.bio/static-files/a14f9b2a-d9aa-4793-aa41-b2eee1fb33e7 5. Ko et al. Nature 2014;514(7524):642-5 9

View entire presentation